GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Cyclically Adjusted Price-to-FCF

Progenics Pharmaceuticals (FRA:PGP) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Progenics Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Progenics Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Progenics Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Progenics Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progenics Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Progenics Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Progenics Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2020 is calculated as:

For example, Progenics Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2020 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2020 (Change)*Current CPI (Mar. 2020)
=-0.117/108.9015*108.9015
=-0.117

Current CPI (Mar. 2020) = 108.9015.

Progenics Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201006 -0.305 91.962 -0.361
201009 -0.290 92.162 -0.343
201012 -0.261 92.474 -0.307
201103 0.846 94.283 0.977
201106 -0.152 95.235 -0.174
201109 -0.117 95.727 -0.133
201112 -0.195 95.213 -0.223
201203 -0.321 96.783 -0.361
201206 -0.201 96.819 -0.226
201209 -0.157 97.633 -0.175
201212 -0.116 96.871 -0.130
201303 -0.086 98.209 -0.095
201306 -0.176 98.518 -0.195
201309 -0.111 98.790 -0.122
201312 -0.117 98.326 -0.130
201403 -0.105 99.695 -0.115
201406 -0.092 100.560 -0.100
201409 -0.002 100.428 -0.002
201412 0.363 99.070 0.399
201503 -0.145 99.621 -0.159
201506 -0.118 100.684 -0.128
201509 -0.125 100.392 -0.136
201512 -0.139 99.792 -0.152
201603 -0.110 100.470 -0.119
201606 -0.072 101.688 -0.077
201609 0.485 101.861 0.519
201612 -0.118 101.863 -0.126
201703 -0.172 102.862 -0.182
201706 -0.161 103.349 -0.170
201709 -0.187 104.136 -0.196
201712 -0.158 104.011 -0.165
201803 -0.160 105.290 -0.165
201806 -0.132 106.317 -0.135
201809 -0.136 106.507 -0.139
201812 -0.095 105.998 -0.098
201903 -0.283 107.251 -0.287
201906 -0.224 108.070 -0.226
201909 -0.208 108.329 -0.209
201912 -0.225 108.420 -0.226
202003 -0.117 108.902 -0.117

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Progenics Pharmaceuticals  (FRA:PGP) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Progenics Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (FRA:PGP) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga 06-16-2023